Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Holding RVMD?
Track your performance easily
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.51 - $62.40
Previous Close$55.13
Volume1.94M
Average Volume (3M)1.18M
Market Cap
$9.27B
Enterprise Value$7.81B
Total Cash (Recent Filing)$1.55B
Total Debt (Recent Filing)$86.71M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 03, 2025EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.59
Shares Outstanding168,219,391
10 Day Avg. Volume1,753,310
30 Day Avg. Volume1,176,230
Standard Deviation0.17
R-Squared0.20
Alpha0.00433
Financial Highlights & Ratios
Price to Book (P/B)5.92
Price to Sales (P/S)13006.40
Price to Cash Flow (P/CF)-18.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.53K
Enterprise Value/Gross Profit674.54
Enterprise Value/Ebitda-14.57
Forecast
1Y Price Target
$66.55Price Target Upside20.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Revolution Medicines News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRevolution Medicines presented preliminary Phase 1/1b results from the RMC-9805-001 trial, showing an objective response rate (ORR) of 30% and a disease control rate of 80% for patients with pancreatic ductal adenocarcinoma, which appears superior to various chemotherapy regimens.
Financial PositionThe company ended the quarter with a strong cash position of roughly $1.55 billion, which is expected to support operations through multiple key data catalysts.
Pipeline ProgressEncouraging clinical data from the innovative RAS(ON) platform, coupled with the large addressable population of RAS-dependent cancers, support a positive long-term outlook for RVMD.
Bears Say
Clinical TrialsThe Phase III trial initiation for RMC-6236 monotherapy in 2L non-small-cell lung cancer (NSCLC) has been pushed to 1Q25 from 4Q24.
Regulatory ApprovalRisks include potential clinical setbacks and inability to secure timely regulatory approval for key drug candidates.
Stock PerformanceThe stock is expected to be flat at best on this data, as RMC-9805 did not differentiate.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $20.51 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Mar 03, 2025 which is in 102 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.047.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$1.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 168,219,390 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Farallon Capital Management, L.L.C.. It holds Revolution Medicines’s shares valued at 379M.
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.55 (20.71% Upside)
$66.55 (20.71% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.34%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
79.12%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q3 2024
0:00 / 0:00
---
RVMD Stock 12 Month Forecast
Average Price Target
$66.55
▲(20.71% Upside)
Technical Analysis
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+63.22%
assigned a buy rating 15 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +63.22% per trade.
---